Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Graft-Versus-Host Disease (GVHD) Clinical Trials

A listing of Graft-Versus-Host Disease (GVHD) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (39) clinical trials

People with acute Graft versus Host Disease (GVHD are asked to participate in a research study being conducted by Montefiore Medical Center

Phase N/A

This is an open-label, single-cohort, multicenter Phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory Grades II to IV acute GVHD.

Phase

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Phase

Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease

A single center non randomized, non blinded Phase I/II clinical trial is proposed to study the role of mesenchymal stem cells (MSC) in the management of steroid refractory graft versus host disease (GVHD) following an allogeneic stem cell transplant. Patients who develop grade II to IV GVHD following an allogeneic ...

Phase

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

Prevention of oral chronic graft verusu host disease (GVHD) by topical agents is an attractive strategy because it would potentially avoid the adverse effects associated with systemic immunosuppression. Topically administered dexamethasone solution is a commonly used agent for the prophylaxis of oral inflammatory conditions including GVHD. However, the efficacy and ...

Phase

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: - Determine the overall survival rate at day 200 in patients with hematologic cancers or other diseases who undergo allogeneic peripheral blood stem cell transplantation using the CliniMACS® CD34 Reagent System for T-cell depletion followed by delayed T-cell add-back. - Determine the safety of this regimen, in terms of ...

Phase

Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell

This is a multicenter, single dose study of allogenic mesenchymal stem cell (1-2 x 10^6 MSC/Kg recipient´s bodyweight). MSC will be infused, by a central venous catheter, to patients diagnosed with GVHD refractory to first-line or subsequent treatment. All patients will receive the same treatment. MSC suspension will be obtained ...

Phase

Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

Blood and skin DC reconstitution shall be investigated in patients affected by hematological diseases and receiving HLA-matched, mobilized peripheral blood stem cells from related or unrelated donors. We plan to simultaneously collect and process double biopsies, i.e. from graft versus host disease affected and non-lesional skin of patients at onset ...

Phase N/A

Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

OBJECTIVES: Primary - Determine the test characteristics of galactomannan (GM) ELISA using serum and bronchoalveolar lavage fluid (BALF) collected from patients at high risk of invasive fungal infection. - Determine the test characteristics of aspergillus PCR using blood and BALF samples collected from these patients. - Evaluate the role of ...

Phase N/A

Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

Graft-versus-host disease (GVHD) contributes substantially to transplant-related morbidity and mortality. Steroids remains first line therapy for acute GVHD but there is currently no consensus on second line therapy for those in whom steroids have been ineffective. Basiliximab has been shown to be a safe and effective immunosuppresant in the prevention ...

Phase N/A